|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Additional file 3: Table S2** Patient baseline demographic and disease characteristics   |  |  |  |  | | --- | --- | --- | --- | |  | **Tofacitinib 5 mg BID**  **(n = 1123)** | **Tofacitinib 10 mg BID**  **(n = 3358)** | **All tofacitinib**  **(n = 4481)** | | Age, mean (SD) | 54.0 (12.1) | 53.0 (11.5) | 53.3 (11.6) | | Female, n (%) | 927 (82.5) | 2744 (81.7) | 3671 (81.9) | | Race, n (%)  White  Black  Asian  Hispanic  Other | 745 (66.3)  28 (2.5)  225 (20.0)  14 (1.2)  111 (9.9) | 2430 (72.4)  112 (3.3)  475 (14.1)  0  341 (10.2) | 3175 (70.9)  140 (3.1)  700 (15.6)  14 (0.3)  452 (10.1) | | BMI, mean (SD) kg/m2 | 27.0 (5.9) | 27.7 (6.5) | 27.5 (6.4) | | Smoking status, n (%)  Never-smoker  Smoker  Ex-smoker  Unknown | 702 (62.5)  177 (15.8)  173 (15.4)  71 (6.3) | 2136 (63.6)  596 (17.7)  622 (18.5)  4 (0.1) | 2838 (63.3)  773 (17.3)  795 (17.7)  75 (1.7) | | Tender joint count, mean (SD) | 22.8 (13.5) | 25.7 (14.9) | 25.0 (14.6) | | Swollen joint count, mean (SD) | 14.7 (8.8) | 15.4 (9.3) | 15.2 (9.2) | | ESR, mean (SD) | 46.2 (25.4) | 49.1 (27.1) | 48.5 (26.7) | | CRP, mean (SD) | 18.3 (22.6) | 18.0 (23.2) | 18.1 (23.1) | | DAS28-4(ESR), mean (SD) | 6.3 (1.0) | 6.4 (1.0) | 6.4 (1.0) | | Duration of disease, mean (SD) years | 8.6 (8.4) | 7.7 (7.9) | 7.9 (8.0) | | CDAI, mean (SD) | 36.4 (13.0) | 37.2 (13.1) | 37.0 (13.1) | | SDAI, mean (SD) | 38.3 (13.7) | 39.0 (13.8) | 38.8 (13.7) | | Positive for rheumatoid factor, n (%) | 791 (75.3) | 2245 (72.2) | 3036 (73.0) | | Positive for anti-citrullinated protein antibody, n (%) | 329 (78.9) | 2297 (75.9) | 2626 (76.3) | | Herpes zoster, n (%)a  Had chicken pox  Received chicken pox vaccine  Received herpes zoster vaccine  Ever had shingles (herpes zoster) once during lifetime | 243 (21.6)  19 (1.7)  44 (3.9)  87 (7.8) | 1048 (31.2)  134 (4.0)  72 (2.1)  366 (10.9) | 1291 (28.8)  153 (3.4)  116 (2.6)  453 (10.1) |   aMany patients unknown for one or more options due to incomplete data collection for duration of study  Baseline qualifying index study data were used for approximately 90% of patients (index baseline data applicable to efficacy/laboratory variables, with disease duration calculated at index baseline; LTE baseline data applicable to demographic variables)  Database lock: March 2, 2017  *BID* twice daily, *BMI* body mass index, *CDAI* Clinical Disease Activity Index, *CRP* C-reactive protein, *DAS28-4(ESR)* Disease Activity Score in 28 joints using erythrocyte sedimentation rate, *ESR* erythrocyte sedimentation rate, *LTE* long-term extension, *SD* standard deviation, *SDAI* Simplified Disease Activity Index |